Study of Azenosertib, a Wee1 Inhibitor, in Women With Recurrent or Persistent Uterine Serous Carcinoma

What this Trial Is About

Researchers are evaluating how the drug Azenosertib affects tumor cells in women with persistent or recurrent uterine serous carcinoma, a type of uterine cancer. This Phase 2 study is sponsored by Dr. Joyce Liu and supported by Zentalis Pharmaceuticals. The study focuses on investigating Azenosertib, a Wee1 inhibitor, which has shown the ability to stop cancer cell growth in other diseases but is not yet FDA-approved for this condition. Participants will receive Azenosertib orally in cycles, taking the drug on days 1 through 5, 8 through 12, and 15 through 19 of each cycle. The study includes about 25 women and involves baseline assessments, CT or MRI scans every two cycles, and an end-of-treatment visit. Biopsies and various imaging scans such as PET-CT, MIBG, and FDG-PET will be performed to monitor disease and treatment effects. During the study, participants will undergo tumor biopsies, blood tests, electrocardiograms, and multiple imaging procedures including CT, MRI, and several specialized scans. Researchers will measure changes in tumor cell replication speed and progression-free survival up to seven months, along with other outcomes such as overall response rate and treatment-related toxicities. The study period includes screening, treatment, and follow-up visits to closely monitor participants health and treatment effects.

Azenosertib in Uterine Serous Carcinoma: Biomarker Study